Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05590585

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial — DISCOVER  

Atopic Eczema Clinical Trial

Official title:
An Open-Label Single-Arm Study of Dupilumab in Adolescent and Adult Skin of Color Patients With Moderate-to-Severe Atopic Dermatitis

Clinical Trial Summary

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants. The study is looking at several other research questions, including: - What side effects may happen from taking the study drug - How much study drug is in your blood at different times - How much the study drug improves quality of life and mental health

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05590585
Study type Interventional
Source Regeneron Pharmaceuticals
Contact Clinical Trials Administrator
Phone 844-734-6643
Email clinicaltrials@regeneron.com
Status Recruiting
Phase Phase 4
Start date January 11, 2023
Completion date July 23, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT02381028 - Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children N/A
Completed NCT00484003 - A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis Phase 4
Recruiting NCT06230991 - A Pilot Study of Efficacy and Safety of SIM05 in Adults With Atopic Eczema N/A
Recruiting NCT05454722 - A Study to Evaluate Adex Gel in the Treatment of Atopic Eczema. N/A
Completed NCT01854580 - Evaluation of an Integrated Care Project
Completed NCT00555178 - Regulatory T Cells (Tregs) in Polymorphic Light Eruption N/A
Completed NCT00559546 - Montelukast as a Controller of Atopic Syndrome Phase 4
Completed NCT00224432 - Double-Blind, Parallel, Randomised Study to Investigate the Effect of Oral Probiotics in Infants With Atopic Dermatitis N/A
Active, not recruiting NCT03143504 - A Longitudinal Investigation of Skin Barrier Development From Birth and the Validation of Early Predictors of Atopic Eczema Risk: the Skin Testing for Atopic Eczema Risk (STAR) Study
Active, not recruiting NCT03409367 - A Community-based Assessment of Skin Care, Allergies, and Eczema N/A
Completed NCT00826592 - Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis N/A
Completed NCT00576238 - Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser Phase 3
Completed NCT01119313 - Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema Phase 2
Completed NCT00676884 - A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema Phase 2
Recruiting NCT03270566 - Softened Water for Eczema Prevention Pilot Trial N/A
Completed NCT02300701 - Role of Anti-IgE in Severe Childhood Eczema Phase 4
Completed NCT04114097 - The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover Phase 4
Completed NCT02915146 - Narrowband Ultraviolet B Versus Narrowband Ultraviolet B Plus Ultraviolet A1 for Atopic Eczema N/A
Recruiting NCT00771121 - Effect of Moisturizing Creams on Skin Barrier Function Phase 4
Completed NCT01179529 - Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage Phase 2